Free Trial

Kiniksa Pharmaceuticals (KNSA) Earnings Date, Estimates & Call Transcripts

Kiniksa Pharmaceuticals logo
$23.36 +0.60 (+2.64%)
Closing price 04:00 PM Eastern
Extended Trading
$23.37 +0.01 (+0.04%)
As of 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kiniksa Pharmaceuticals Latest Earnings Summary

Upcoming Q1
Earnings Date
Apr. 22Before Market OpensEstimated
Actual EPS
(Feb. 25)
-$0.12 Missed By -$0.06
Consensus EPS
(Feb. 25)
-$0.06

Kiniksa Pharmaceuticals posted Q4 2024 earnings on February 25, 2025, reporting an EPS of -$0.12, which missed analysts' consensus estimates of -$0.06 by $0.06. Quarterly revenue rose 46.9% year-over-year to $122.50 million, below the consensus estimate of $123.42 million. With a trailing EPS of -$0.61, Kiniksa Pharmaceuticals' earnings are expected to grow next year, from ($0.55) to $0.25 per share.

KNSA Upcoming Earnings

Kiniksa Pharmaceuticals' next earnings date is estimated for Tuesday, April 22, 2025, based off prior year's reporting schedules.

Get Kiniksa Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kiniksa Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

KNSA Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

KNSA Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.
Remove Ads

Kiniksa Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20251$0.31$0.31$0.31
Q2 20251$0.38$0.38$0.38
Q3 20251$0.47$0.47$0.47
Q4 20251$0.52$0.52$0.52
FY 20254$1.68$1.68$1.68
Remove Ads

Kiniksa Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
4/22/2025
(Estimated)
-------
2/25/2025Q4 2024-$0.06-$0.12 -$0.06-$0.12$123.42M$122.50M
10/29/2024Q3 2024-$0.01-$0.18 -$0.17-$0.18$111.51M$112.21M
7/23/2024Q2 2024-$0.09-$0.06+$0.03-$0.06$90.60M$108.30M
4/23/2024Q1 2024-$0.14-$0.25 -$0.11-$0.25$76.97M$79.90M
2/28/2024Q4 2023-$0.11$0.04+$0.15-$0.27$72.31M$83.40M
10/31/2023Q3 2023-$0.18-$0.20 -$0.02-$0.20$62.53M$67.05M
7/25/2023Q2 2023-$0.16-$0.02+$0.14-$0.25$52.33M$71.47M
5/2/2023Q1 2023-$0.18-$0.18--$0.18$45.95M$48.35M

Kiniksa Pharmaceuticals Earnings - Frequently Asked Questions

Kiniksa Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, April 22nd, 2025 based off last year's report dates. Learn more on KNSA's earnings history.

Kiniksa Pharmaceuticals updated its FY 2025 earnings guidance on Friday, February, 28th. The company issued revenue guidance of $560.0 million-$580.0 million, compared to the consensus revenue estimate of $581.4 million.

In the previous quarter, Kiniksa Pharmaceuticals (NASDAQ:KNSA) missed the analysts' consensus estimate of ($0.06) by $0.06 with a reported earnings per share (EPS) of ($0.12). Learn more on analysts' earnings estimate vs. KNSA's actual earnings.

The conference call for Kiniksa Pharmaceuticals's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Kiniksa Pharmaceuticals's latest earnings report can be read online.
Read Transcript

Kiniksa Pharmaceuticals (NASDAQ:KNSA) has a recorded annual revenue of $423.24 million.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) has a recorded net income of $14.08 million. KNSA has generated -$0.61 earnings per share over the last four quarters.

Kiniksa Pharmaceuticals's earnings are expected to grow from ($0.55) per share to $0.25 per share in the next year.

More Earnings Resources from MarketBeat

Remove Ads


This page (NASDAQ:KNSA) was last updated on 3/27/2025 by MarketBeat.com Staff
From Our Partners